Ventyx Biosciences, Inc. $VTYX Shares Sold by Cibc World Market Inc.

Cibc World Market Inc. reduced its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 39.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,250 shares of the company’s stock after selling 99,750 shares during the period. Cibc World Market Inc. owned about 0.22% of Ventyx Biosciences worth $483,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. CWM LLC increased its position in shares of Ventyx Biosciences by 7.6% in the second quarter. CWM LLC now owns 57,145 shares of the company’s stock valued at $122,000 after buying an additional 4,057 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in Ventyx Biosciences in the 2nd quarter valued at about $34,000. Engineers Gate Manager LP purchased a new position in Ventyx Biosciences during the 2nd quarter valued at about $42,000. Vanguard Personalized Indexing Management LLC raised its position in Ventyx Biosciences by 104.1% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 46,711 shares of the company’s stock worth $100,000 after acquiring an additional 23,828 shares during the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Ventyx Biosciences in the second quarter valued at about $53,000. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on VTYX shares. Oppenheimer lowered shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 8th. Wells Fargo & Company reiterated an “equal weight” rating and set a $14.00 target price on shares of Ventyx Biosciences in a report on Thursday, January 8th. Clear Str cut Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 7th. Canaccord Genuity Group downgraded Ventyx Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $16.00 to $14.00 in a research report on Thursday, January 8th. Finally, Piper Sandler lowered Ventyx Biosciences from an “overweight” rating to a “hold” rating and set a $14.00 price objective on the stock. in a research note on Thursday, January 8th. Eight investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $14.00.

Ventyx Biosciences Stock Up 0.1%

Shares of Ventyx Biosciences stock opened at $13.96 on Thursday. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $25.00. The business’s fifty day moving average is $11.94 and its two-hundred day moving average is $7.51. The firm has a market cap of $1.00 billion, a PE ratio of -9.31 and a beta of 1.25.

Insider Transactions at Ventyx Biosciences

In related news, insider John Nuss sold 12,675 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider directly owned 489,481 shares in the company, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total transaction of $365,503.40. Following the transaction, the chief executive officer directly owned 2,372,863 shares in the company, valued at approximately $18,318,502.36. This represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. 14.49% of the stock is currently owned by company insiders.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.